* Magenta Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 2 (estimated).
*
* Refinitiv's mean analyst estimate for Magenta Therapeutics Inc is for a loss of 19 cents per share.
* The one available analyst rating on the shares is "hold".
* The mean earnings estimate of analysts had fallen by about 24.2% in the last three months.
* Wall Street's median 12-month price target for Magenta Therapeutics Inc is $1, above its last closing price of $0.81.
This summary was machine generated July 31 at 16:00 GMT. All figures in US dollars unless otherwise stated.